Advertisement
IQV or MEDP or RVTY
Which Stock Would AI Choose? IQVIA Holdings (IQV) vs. Medpace Holdings (MEDP) vs. Revvity (RVTY) Stock Comparison
Key Takeaways
- IQV leads year-to-date (YTD) performance among the three at approximately +30%, driven by its dominant position in biopharmaceutical services.
- MEDP posted a Q1 revenue beat in recent earnings but experienced a sharp post-report pullback amid concerns over booking trends, with YTD gains near +26%.
- RVTY trails YTD at +10%, offering relative stability in life sciences tools, supported by recent dividend declarations and product launches.
- All three stocks operate in the healthcare services sector, with upcoming Q1 earnings reports anticipated to influence near-term momentum.
- IQV boasts the largest market cap at $26B, while MEDP shows superior profit margins around 17%.
- Valuations vary, with IQV's trailing P/E (price-to-earnings ratio) at 20x appearing most attractive relative to peers.
Introduction
This comparison examines IQV, MEDP, and RVTY, three prominent players in healthcare services and life sciences. These stocks appeal to investors tracking contract research organizations (CROs) and diagnostics providers amid evolving biopharma demand. Traders focused on relative performance, sector momentum, and upcoming catalysts will find value in understanding their business models, recent price behaviors, and market positioning in the current environment.
IQV Overview and Recent Performance
IQV, or IQVIA Holdings Inc., is the world's largest provider of biopharmaceutical development and commercial outsourcing services, supporting drug discovery, trials, and real-world evidence. In recent market activity, the stock has navigated volatility, with shares trading around $158 amid a 52-week range of $135 to $247. YTD gains exceed 30%, outperforming peers, though recent weeks saw pressure from AI-related investor concerns despite in-line prior results and launches like IQVIA.ai with NVIDIA. Upcoming Q1 earnings are expected to highlight revenue around $4.1B, influencing sentiment on growth in its Technology & Analytics segment.
MEDP Overview and Recent Performance
Medpace Holdings, Inc. (MEDP) specializes in clinical research services for drugs and medical devices, emphasizing full-service CRO operations. Shares recently hovered near $418, within a 52-week range of $284 to $629. Recent earnings revealed Q1 revenue of $707M, surpassing estimates with 27% year-over-year growth and raised full-year guidance, yet the stock dropped nearly 20% post-report due to softer-than-expected bookings and net new awards. YTD performance stands at +26%, reflecting robust backlog execution despite award cycle fluctuations.
RVTY Overview and Recent Performance
Revvity, Inc. (RVTY), formerly PerkinElmer, focuses on life sciences tools, diagnostics, and discovery services. Trading around $87 in recent weeks, its 52-week range spans $81 to $118, with YTD returns at +10%. Sentiment has been steady, bolstered by a quarterly dividend declaration, new product unveilings like Signals BioDesign for molecular cloning, and investor conference presentations. Q1 earnings loom, with focus on revenue near $705M and ongoing integration in its reagents and consumables segments.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top performers from hundreds of AI trading bots that analyze and trade thousands of tickers across stocks, ETFs, and crypto. Only 25 bots earn a spot in this section based on suitability for current market conditions, showcasing diverse strategies like AI/ML pattern recognition, with timeframes from 5 minutes to 60 days. Standout stats include annualized returns of 24% to 163%, win rates from 51% to 88%, and profit factors up to 11.7, spanning sectors from semiconductors to industrials. Virtual agents incorporate risk management such as take-profit/stop-loss corridors. Traders can explore these high-conviction signals for potential edge in volatile markets.
Head-to-Head Comparison
IQV, MEDP, and RVTY share healthcare exposure but diverge in models: IQV's scale ($26B market cap) drives diversified CRO and analytics revenue; MEDP's focused CRO yields top margins (17%) and ROE (77%); RVTY emphasizes tools/diagnostics with lower growth but beta near 1.0 for stability. Recent momentum favors IQV's YTD lead, while MEDP's volatility highlights award sensitivity versus RVTY's steadier path. Risks include biopharma funding cycles for CROs and reimbursement for diagnostics; valuations show IQV cheapest at 20x P/E, RVTY priciest at 42x. Sentiment tilts toward growth names like MEDP amid GLP-1 tailwinds, balanced by IQV's real-world data moat.
Tickeron AI Verdict
Tickeron’s AI models currently lean toward IQV for its consistent YTD momentum, attractive valuation, and broad catalysts like AI integrations ahead of earnings. While MEDP offers superior growth prospects and RVTY provides defensive positioning, IQV's relative stability and scale position it favorably in recent trend analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IQV’s FA Score shows that 0 FA rating(s) are green whileMEDP’s FA Score has 2 green FA rating(s), and RVTY’s FA Score reflects 2 green FA rating(s).
- IQV’s FA Score: 0 green, 5 red.
- MEDP’s FA Score: 2 green, 3 red.
- RVTY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IQV’s TA Score shows that 5 TA indicator(s) are bullish while MEDP’s TA Score has 6 bullish TA indicator(s), and RVTY’s TA Score reflects 3 bullish TA indicator(s).
- IQV’s TA Score: 5 bullish, 4 bearish.
- MEDP’s TA Score: 6 bullish, 4 bearish.
- RVTY’s TA Score: 3 bullish, 6 bearish.
Price Growth
IQV (@Medical Specialties) experienced а -1.08% price change this week, while MEDP (@Medical Specialties) price change was +2.88% , and RVTY (@Medical Specialties) price fluctuated +1.31% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.27%. For the same industry, the average monthly price growth was +8.03%, and the average quarterly price growth was -5.20%.
Reported Earning Dates
IQV is expected to report earnings on Jul 28, 2026.
MEDP is expected to report earnings on Jul 27, 2026.
RVTY is expected to report earnings on Aug 03, 2026.
Industries' Descriptions
@Medical Specialties (-0.27% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| IQV | MEDP | RVTY | |
| Capitalization | 30.3B | 13.3B | 11.1B |
| EBITDA | 3.52B | 591M | 773M |
| Gain YTD | -19.498 | -16.792 | 3.151 |
| P/E Ratio | 22.54 | 29.41 | 47.91 |
| Revenue | 16.6B | 2.68B | 2.9B |
| Total Cash | 2.1B | 653M | 860M |
| Total Debt | 16.1B | 122M | 3.35B |
IQV | MEDP | RVTY | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 13 | 28 | 24 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 62 Fair valued | 78 Overvalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 37 | 100 | |
SMR RATING 1..100 | 42 | 15 | 89 | |
PRICE GROWTH RATING 1..100 | 51 | 47 | 49 | |
P/E GROWTH RATING 1..100 | 49 | 30 | 32 | |
SEASONALITY SCORE 1..100 | 75 | 85 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RVTY's Valuation (15) in the Medical Specialties industry is somewhat better than the same rating for IQV (62) in the Servicestothe Health Industry industry, and is somewhat better than the same rating for MEDP (78) in the Miscellaneous Commercial Services industry. This means that RVTY's stock grew somewhat faster than IQV’s and somewhat faster than MEDP’s over the last 12 months.
MEDP's Profit vs Risk Rating (37) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for RVTY (100) in the Medical Specialties industry, and is somewhat better than the same rating for IQV (100) in the Servicestothe Health Industry industry. This means that MEDP's stock grew somewhat faster than RVTY’s and somewhat faster than IQV’s over the last 12 months.
MEDP's SMR Rating (15) in the Miscellaneous Commercial Services industry is in the same range as IQV (42) in the Servicestothe Health Industry industry, and is significantly better than the same rating for RVTY (89) in the Medical Specialties industry. This means that MEDP's stock grew similarly to IQV’s and significantly faster than RVTY’s over the last 12 months.
MEDP's Price Growth Rating (47) in the Miscellaneous Commercial Services industry is in the same range as RVTY (49) in the Medical Specialties industry, and is in the same range as IQV (51) in the Servicestothe Health Industry industry. This means that MEDP's stock grew similarly to RVTY’s and similarly to IQV’s over the last 12 months.
MEDP's P/E Growth Rating (30) in the Miscellaneous Commercial Services industry is in the same range as RVTY (32) in the Medical Specialties industry, and is in the same range as IQV (49) in the Servicestothe Health Industry industry. This means that MEDP's stock grew similarly to RVTY’s and similarly to IQV’s over the last 12 months.
| IQV | MEDP | RVTY | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 80% | 3 days ago 77% |
| Stochastic ODDS (%) | 3 days ago 68% | 3 days ago 60% | 3 days ago 69% |
| Momentum ODDS (%) | 3 days ago 66% | 3 days ago 82% | 3 days ago 72% |
| MACD ODDS (%) | 3 days ago 63% | 3 days ago 75% | 3 days ago 74% |
| TrendWeek ODDS (%) | 3 days ago 64% | 3 days ago 74% | 3 days ago 65% |
| TrendMonth ODDS (%) | 3 days ago 63% | 3 days ago 75% | 3 days ago 60% |
| Advances ODDS (%) | 6 days ago 58% | 6 days ago 74% | 6 days ago 66% |
| Declines ODDS (%) | 4 days ago 65% | 19 days ago 64% | 13 days ago 67% |
| BollingerBands ODDS (%) | 3 days ago 54% | 3 days ago 61% | 3 days ago 71% |
| Aroon ODDS (%) | 3 days ago 51% | 3 days ago 76% | 3 days ago 52% |
Advertisement
IQV and
Correlation & Price change
A.I.dvisor indicates that over the last year, IQV has been closely correlated with CRL. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if IQV jumps, then CRL could also see price increases.
| Ticker / NAME | Correlation To IQV | 1D Price Change % | ||
|---|---|---|---|---|
| IQV | 100% | +0.22% | ||
| CRL - IQV | 75% Closely correlated | -0.29% | ||
| TMO - IQV | 71% Closely correlated | -1.33% | ||
| MEDP - IQV | 69% Closely correlated | -1.63% | ||
| RVTY - IQV | 66% Loosely correlated | -1.83% | ||
| A - IQV | 63% Loosely correlated | +0.22% | ||
More | ||||
MEDP and
Correlation & Price change
A.I.dvisor indicates that over the last year, MEDP has been loosely correlated with IQV. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if MEDP jumps, then IQV could also see price increases.
| Ticker / NAME | Correlation To MEDP | 1D Price Change % | ||
|---|---|---|---|---|
| MEDP | 100% | -1.63% | ||
| IQV - MEDP | 66% Loosely correlated | +0.22% | ||
| CRL - MEDP | 52% Loosely correlated | -0.29% | ||
| TMO - MEDP | 46% Loosely correlated | -1.33% | ||
| BRKR - MEDP | 43% Loosely correlated | -1.72% | ||
| RVTY - MEDP | 39% Loosely correlated | -1.83% | ||
More | ||||